We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock

Delisted

SEEL was delisted on the 15th of October, 2024.

20 hedge funds and large institutions have $2.55M invested in Seelos Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

54% more funds holding

Funds holding: 1320 (+7)

30% less capital invested

Capital invested by funds: $3.66M → $2.55M (-$1.11M)

Holders
20
Holders Change
+7
Holders Change %
+53.85%
% of All Funds
0.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
6
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change

SEEL Hedge Fund Activity: Q1 2020 in Review

20 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2020, worth a combined $2.55M — down 30% from $3.66M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SEEL positions and 1 closed out — a net gain of 8 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Uniplan Investment Counsel, adding an estimated $1.36M. The largest seller was MYCIO Wealth Partners, exiting entirely with an estimated $41K sold.

  • 20 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2020, up from 13 in Q4 2019.
  • Funds reported $2.55M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2020, down 30% quarter-over-quarter.
  • 9 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2020 and 1 closed out, a net change of +8 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2020 was Uniplan Investment Counsel, an estimated $1.36M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2020 was MYCIO Wealth Partners, an estimated $41K sold.

Based on aggregated 13F filings for Q1 2020.